Başak Bala USTAALİOĞLU ÖVEN, Ahmet BİLİCİ, Mesut ŞEKER, Taflan SALEPÇİ, Emre YILDIRIM, Umut KEFELİ, Metin KEMENT, Mahmut GÜMÜŞ

Inflammatory Breast Cancer: Single Çenter Experience

İnflamatuvar meme kanseri (İMK), meme kanserlerinin %1-6'sını oluşturup, lokal ileri meme kanserine göre daha kötü prog-nozludur. İMK'li 41 hasta retrospektif olarak değerlendirildi. Hastalıksız sağkalım (DFS), gene! sağkalım (OS) ve prognostik faktörler univariyete analiziyle değerlendirildi. Hastaların median yaşı 46 idi. Tanı sonrası 28 (%68) hasta öpere olabildi. Yirmi bir (%51) hastaya median iki kür neoadjuvan kemoterapi (KT) verilmişti. Adjuvan KT olarak antrasiklinli ve taksanlı rejimler kullanılmıştı, %66 hasta adjuvan radyoterapi verilmişti. Median 19 ay takip edilen hastaların üç yıllık OS ve DFS oranları sırasıyla %81 ve %49.8 idi. Median DFS 28.8 ayken, median OS zamanına ulaşılamadı. Univariyete analizinde, neoadjuvan KT OS'u, perinö-rat invazyon, c-erbB2 pozitifliği ise DFS'yi predikte eden faktörler olarak bulundu (p< 0.05). Multivariyete analizinde ise sağkalım predikte eden faktör saptanmadı (p> 0.05). Yeni gelişmelere rağmen, İMK günümüzde halen hızlı progresyon ve uzak metastaz yapma riskine sahiptir. Daha fazla hasta sayısı içeren çalışmalara ihtiyaç vardır.

Anahtar Kelimeler:

İnflamatuvar meme kanseri, prognoz, sağkalım.

İnflamatuvar Meme Kanseri Serimiz: Tek Merkez Deneyimi

Inflammatory breast cancer (IBC) is the %1-6of breast cancer and had a worse prognosis than locally advanced breast cancer. Forty-one patients with IBC were analysed retrospectively. Disease free sun/ival (DFS), overall survival (OS), prognostic fac-tors were evaluated by univariety analysis. Median age of patients was 46. After the diagnosis, 28 patients underwent mastectomy. Median two cycles of neoadjuvant chemotherapy (CT) was given to 51% patients. Taxanes and antracyclines included regi-mens were given as adjuvant CT and also adjuvant radiotherapy was given 66% of patients. For the 19 months of follow-up time, three years OS and DFS rates were 81% and 49.8% respectively. Median DFS was 28.8 months, median OS was not reached. We found that neoadjuvant CT was related OS, perineural invasion, c-erbB2 expression was related with DFS by univariety analysis (p< 0.05). Hovevver, there was not any prognostic factor related survival by multivariety analysis. IBC stili has bad prognosis, larger studies with more patients are needed.

Keywords:

Inflammatory breast cancer, prognosis, survival.,

PDF

___

Molckovsky A, Fitzgerald B, Freedman O, Heisey R, Clemons M. Approach to inflammatory breast cancer. Can Fam Physician 2009;55:25-31.
Levine PH, Veneroso C. The epidemiology of inflammatory breast cancer. Semin Oncol 2008;35:11-6.
Chia S, Swain SM, Byrd DR, Mankoff DA. Locally advanced and inflammatory breast cancer. J d in Oncol 2008;26:786- 90.
Low JA, Berman AW, Steinberg SM, Danforth DN, Lippman ME, Swain SM. Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multi- modality therapy. J Clin Oncol 2004;22:4067-74.
Anderson JM. İnflammatory carcinomas of the breast. Ann R Coll Surg Engl 1980;62:195-9.
Lerebours F, Bieche I, Lidereau R. Update on inflammatory breast cancer. Breast Cancer Res 2005;7:52-8.
Bonnier P, Charpin C, Lejeune C, Romain S, Tubiana N, Beedassy B. Inflammatory carcinomas of the breast: A clini- cal, pathological, ora clinical andpathologicaldefinition? Int J Cancer 1995;62:382-5.
Charafe-Jauffret E, Tarpin C, Bardou VJ, Bertucci F,
Ginestier C, Braud AC. Immunophenotypic analysis of ınflammatory breast cancers: Identification of an “inflamma- tory signature”. J Pathol 2004;202:265-73.
Mathew A, Pandey M, Rajan B. Do younger women with non-metastatic and non-inflammatory breast carcinoma have poor prognosis? World J Surg Oncoi 2004;2:2.
Kroman N, Jensen MB, VVohlfahrt J, Mouridsen HT, Andersen PK, Melbye M. Factors influencing the effect of age on prognosis in breast cancer: Population based study. BMJ 2000;320:474-8.
Vanlemmens L, Hebbar M, Pey rat JP, Bonneterre J. Age as a prognostic factor in breast cancer. Anticancer Res 1998;18:1891-6.
Chung M, Chang HR, Bland Kİ, Wanebo HJ. Younger women with breast carcinoma have a poorer prognosis than older women. Cancer 1996;77:97-103.
Betta PG, Robutti F, Spinoglio G, Bottero G. A multivariate analysis of the prognostic significance of pathological featu- res in breast cancer of perimenopausal age. Pathologica 1988;80:287-92.
Crowe JP Jr, Gordon NH, Shenk RR, Zollinger RM Jr, Brumberg DJ, Shuck JM. Age does not predict breast can cer outcome. Arch Surg 1994;129:483-7.
Somlo G, Frankel P, Chow W, Leong L, Margolin K, Morgan R Jr. Prognostic indicators and survival in patients with stage IIIB inflammatory breast carcinoma after dose-intense chemotherapy. J Clin Oncoi 2004;22:1839-48
Bertucci F, Tarpin C, Charafe-Jauffret E, Bardou VJ, Braud AC, Tallet A. Multivariate analysis of survival in inflammatory bre ast cancer: Impact of intensity of chemotherapy in multimoda- lity treatment. Bone Marrow Transplant 2004;33:913-20.
Prost S, Le MG, Douc-Rasy S, Ahomadegbe JC, Spielmann M, Guerin M. Association of c-erbB2-gene amplification with poor prognosis in non-inflammatory breast carcinomas but not in carcinomas of the inflammatory type. Int J Cancer 1994;58:763-8.
Turpin E, Bieche I, Bertheau P, Plassa LF, Lerebours F, de Roquancourt A. Increased incidence o f ERBB2 overexpres- sion and TP53 mutation in inflammatory breast cancer. Oncogene 2002;21:7593-7.
Saydam BK, Göksel G, Korkmaz E, Zeki oğlu O, Kapkac M, Sanli UA. Comparison of inflammatory breast cancer and noninflammatory breast cancer in VVestern Turkey. Med Princ Pract 2008:475-80.
Zell JA, Tsang WY, Taylor TH, Mehta RS, Anton-Culver H. Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): Analysis of 2.014 IBC patient cases from the California Cancer Registry. Breast Cancer Res 2009;11:R9.
Buzdar AU, Valero V, İbrahim NK, Francis D, Broglio KR, Theriault RL. Neoadjuvant therapy with paclitaxel follovved by 5-fluorouracil, epirubicin, and cydophosphamide che motherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: An update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 2007;13:228-33.
Horiguchi J, Oyama T, Koibuchi Y, Yokoe T, Takata D, Ikeda F. Neoadjuvant weekly paclitaxel with and vvithout trastuzu mab in locally advanced or metastatic breast cancer. Anticancer Res 2009;29:517-24.
Shimizu C, Masuda N, Yoshimura K, Tsuda H, Mano M, Ando M. Long-term outcome and pattern of relapse after neoadjuvant chemotherapy in patients with human epider mal growth factor receptor 2-positive primary breast cancer. Jpn J Clin Oncoi 2009;39:484-90.
Dawood S, Broglio K, Gong Y, Yang WT, Cristofanilli M, Kau SW. İnflammatory Breast Cancer Research Group. Prognostic significance of HER-2 status in women with inflammatory breast cancer. Cancer 2008;112:1905-11.
Sawaki M, Ito Y, Akiyama F, Tokudome N, Horii R, Mizunuma N. High prevalence of HER-2/neu and p53 ove- rexpression in inflammatory breast cancer. Breast Cancer 2006;13:172-8.
Ben Hamida A, Labidi IS, Mrad K, Charafe-Jauffret E, Ben Arab S, Esterni B. Markers of subtypes in inflammatory bre ast cancer studied by immunohistochemistry: Prominent expression of P-cadherin. BMC Cancer 2008;8:28.
Cristofanilli M, Buzdar AU, Hortobâgyi GN. Update on the management of inflammatory breast cancer. Oncologist 2003;8:141-8.
Piera JM, Alonso MC, Ojeda MB, Biete A. Locally advanced breast cancer with inflammatory component: A clinical entity with a poor prognosis. Radiother Oncoi 1986;7:199-204.
Low JA, BermanAVV, Steinberg SM, Danforth DN, Lippman ME, Swain SM. Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multi- modality therapy. J Clin Oncoi 2004;22:4067-74.
Bristol IJ, Woodward WA, Strom EA, Cristofanilli M, Domain D, Singletary SE. Locoregional treatment outcomes after multimodality management of inflammatory breast cancer. Int J Radiat Oncoi Biol Phys 2008;72:474-84.
Gruber G, Ciriolo M, Altermatt HJ, Aebi S, Berclaz G, Greiner RH. Prognosis of dermal lymphatic invasion with or without clinical signs of inflammatory breast cancer. Int J Cancer 2004;109:144-8.
Chen JH, Mehta RS, Nalcioglu O, Su MY. İnflammatory bre ast cancer after neoadjuvant chemotherapy: Can magnetic resonance imaging preciseiy diagnose the final pathological response? Ann Surg Oncoi 2008;15:3609-13.
Bonnier P, Charpin C, Lejeune C, Romain S, Tubiana N, Beedassy B. İnflammatory carcinomas of the breast: A clini cal, pathological, or a clinical and pathological definition ? Int J Cancer 1995;62:382-5.
Ellis GK, Livingston RB, Gralow JR, Green SJ, Thompson T. Dose-dense anthracydine-based chemotherapy for node- positive breast cancer. J Clin Oncoi 2002;20:3637-43.
Cetintaş SK, Kurt M, Özkan L, Engin K, Gökgöz S, Taşdelen I. Factors influencing axillary node metastasis in breast can cer. Tumori 2006;92:416-22.
Duraker N, Caynak ZC, Türköz K. Perineurat invasion has no prognostic value in patients with invasive breast carcino ma. Breast 2006;15:629-34.